(Reuters) – China’s Bio-Thera Solutions Ltd has won a regulatory approval for its version of AbbVie Inc’s blockbuster rheumatoid arthritis treatment Humira, paving the way for the first such biosimilar to enter the world’s second-largest drug market. Humira is the world’s top-selling drug, with sales of $20 billion last year, but now faces competition from cheaper versions in Europe and a 2023 expiration of its patents in the United States, by far the most profitable market. The National Medical Products Administration (NMPA), in a statement on its website on Thursday, said Bio-Thera’s Qletli “was highly similar to the approved reference



This content is restricted to site members. If you are an existing user, please log in. New users may register too.